Ludmila Andrade Alves Ferreira, Mário Jorge Sobreira da Silva, Patricia Ribeiro Portella de Araújo, Maely Peçanha Fávero Retto
{"title":"Association between trastuzumab treatment interruption and survival in HER2-positive metastatic breast cancer patients: a retrospective study.","authors":"Ludmila Andrade Alves Ferreira, Mário Jorge Sobreira da Silva, Patricia Ribeiro Portella de Araújo, Maely Peçanha Fávero Retto","doi":"10.1080/1120009X.2025.2485520","DOIUrl":null,"url":null,"abstract":"<p><p>This retrospective study analyzed the effect of trastuzumab treatment interruption on overall survival (OS) and progression-free survival (PFS) within two years after diagnosis in women with HER2-positive metastatic breast cancer. Sociodemographic, clinicopathological, and therapeutic variables were collected from medical records of patients diagnosed between 2013 and 2017 at a comprehensive cancer care center in Brazil. Survival estimates were performed using the Kaplan-Meier method and the log-rank test. The Cox Regression model was used to estimate the risk of outcomes. The average OS was 20.2 months, and the PFS was 13.1 months. Interruption of trastuzumab treatment was associated with an increase in overall survival time compared with continued treatment (22.5 months; 95% CI: 21.8 - 23.3 vs. 17.7 months; 95% CI: 15.9 - 19.4; <i>P</i> = 0.001). The adjusted risk model revealed that continued trastuzumab therapy was independently associated with a 2.86-fold increased risk of mortality.</p>","PeriodicalId":15338,"journal":{"name":"Journal of Chemotherapy","volume":" ","pages":"1-10"},"PeriodicalIF":1.9000,"publicationDate":"2025-04-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Chemotherapy","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1080/1120009X.2025.2485520","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"INFECTIOUS DISEASES","Score":null,"Total":0}
引用次数: 0
Abstract
This retrospective study analyzed the effect of trastuzumab treatment interruption on overall survival (OS) and progression-free survival (PFS) within two years after diagnosis in women with HER2-positive metastatic breast cancer. Sociodemographic, clinicopathological, and therapeutic variables were collected from medical records of patients diagnosed between 2013 and 2017 at a comprehensive cancer care center in Brazil. Survival estimates were performed using the Kaplan-Meier method and the log-rank test. The Cox Regression model was used to estimate the risk of outcomes. The average OS was 20.2 months, and the PFS was 13.1 months. Interruption of trastuzumab treatment was associated with an increase in overall survival time compared with continued treatment (22.5 months; 95% CI: 21.8 - 23.3 vs. 17.7 months; 95% CI: 15.9 - 19.4; P = 0.001). The adjusted risk model revealed that continued trastuzumab therapy was independently associated with a 2.86-fold increased risk of mortality.
期刊介绍：
The Journal of Chemotherapy is an international multidisciplinary journal committed to the rapid publication of high quality, peer-reviewed, original research on all aspects of antimicrobial and antitumor chemotherapy.
The Journal publishes original experimental and clinical research articles, state-of-the-art reviews, brief communications and letters on all aspects of chemotherapy, providing coverage of the pathogenesis, diagnosis, treatment, and control of infection, as well as the use of anticancer and immunomodulating drugs.
Specific areas of focus include, but are not limited to:
· Antibacterial, antiviral, antifungal, antiparasitic, and antiprotozoal agents;
· Anticancer classical and targeted chemotherapeutic agents, biological agents, hormonal drugs, immunomodulatory drugs, cell therapy and gene therapy;
· Pharmacokinetic and pharmacodynamic properties of antimicrobial and anticancer agents;
· The efficacy, safety and toxicology profiles of antimicrobial and anticancer drugs;
· Drug interactions in single or combined applications;
· Drug resistance to antimicrobial and anticancer drugs;
· Research and development of novel antimicrobial and anticancer drugs, including preclinical, translational and clinical research;
· Biomarkers of sensitivity and/or resistance for antimicrobial and anticancer drugs;
· Pharmacogenetics and pharmacogenomics;
· Precision medicine in infectious disease therapy and in cancer therapy;
· Pharmacoeconomics of antimicrobial and anticancer therapies and the implications to patients, health services, and the pharmaceutical industry.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
